Skip to main content

Lupus clinical trials at UC Health
22 in progress, 8 open to new patients

  • A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

    open to eligible people ages 18-70

    This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.

    at UCSD

  • A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

    open to eligible people ages 18 years and up

    The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus erythematosus. Approximately 280 subjects with a documented diagnosis of SLE will be randomized 2:2:1:2 to receive CC-220 (0.45 mg QD, 0.3 mg QD or 0.15 mg QD) or identically appearing placebo.

    at UCLA UCSD

  • An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus

    open to eligible people ages 18-75

    This study will investigate BMS-986165 to assess its effects in patients with systemic lupus erythematosus (SLE).

    at UCLA

  • Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

    open to eligible people ages 18 years and up

    This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.

    at UCLA

  • Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

    open to eligible people ages 18 years and up

    The purpose of this registry is to collect additional information regarding the side effects and effectiveness of BENLYSTA (belimumab) when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). Information will be collected on serious events that are not that common or may only be seen with long-term treatment. These events include death, cancers, serious infections and other infections of interest, and serious mental health problems. Information on the effectiveness of BENLYSTA will also be collected.

    at UCLA

  • Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)

    open to eligible people ages 18-75

    The primary objective of this study is to evaluate the efficacy of filgotinib and GS-9876 in adults with Lupus Membranous Nephropathy (LMN).

    at UCSD

  • Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

    open to eligible people ages 18-70

    The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).

    at UCLA

  • Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

    open to eligible people ages 18-75

    The primary purpose of the study is to evaluate the efficacy of BIIB059 in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, including discoid lupus erythematosus (DLE)) with or without systemic manifestations (Part B). The secondary objective is to evaluate additional efficacy parameters of BIIB059 in reducing SLE/CLE disease activity, pharmacokinetic parameters, safety and tolerability of BIIB059 (Parts A and B).

    at UC Irvine

  • A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

    Sorry, in progress, not accepting new patients

    To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

    at UCLA UC Irvine UCSD UCSF

  • A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.

    at UCSF UCLA

  • A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

    Sorry, not currently recruiting here

    The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

    at UCLA

  • A Study of Baricitinib in Participants With Systemic Lupus Erythematosus

    Sorry, not currently recruiting here

    The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

    at UCSD

  • A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

    Sorry, in progress, not accepting new patients

    This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

    at UCSD

  • Autologous Polyclonal Tregs for Lupus

    Sorry, in progress, not accepting new patients

    The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus. Targeting cutaneous disease offers the ability to control background therapy, readily detect clinical effects, and perform research analyses not only in blood but also skin. Safety, disease activity, and mechanism of Tregs will be evaluated. The intent is to support dose selection for a future larger efficacy trial in lupus.

    at UCSF

  • JBT-101 in Systemic Lupus Erythematosus (SLE)

    Sorry, not currently recruiting here

    The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE). - One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their systemic lupus erythematosus (SLE) with JBT-101. JBT-101 is a synthetic endocannabinoid receptor type 2 (CB2) agonist and an activator of the body's normal processes, to resolve innate immune responses without immunosuppression. - Participants will receive 2 doses of JBT-101 by mouth (three groups of varying doses) or, placebo, for 84 days and will continue to be followed for an additional 28 days. Participant visits to assess endpoints occur on Day 1, then every 2 weeks twice, then every 4 weeks three times, for a total of six visits. - The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit 1) will be assessed at every visit.

    at UCSD UCLA UCSF

  • Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

    Sorry, in progress, not accepting new patients

    The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.

    at UCLA

  • Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.

    at UCSD

  • Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

    Sorry, in progress, not accepting new patients

    This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.

    at UCSD UCSF

  • Rituximab and Belimumab for Lupus Nephritis

    Sorry, in progress, not accepting new patients

    In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.

    at UCLA UCSF

  • Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

    Sorry, in progress, not accepting new patients

    This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).

    at UCLA

  • Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus

    Sorry, in progress, not accepting new patients

    This is a study to determine if people with Lupus have weak bones. Test which is a better method for detecting bone changes: - Dual energy X-ray absorptiometry (DXA) - Single energy quantitative computed tomography (SEQCT) Evaluate whether weak bones are associated with things like medications or amount of fat and muscle.

    at UCSF

  • Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)

    Sorry, not currently recruiting here

    SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health status assessments (PROs), and health care resource utilization (HCRU) in a general population of moderate-to-severe SLE patients.

    at UCLA UCSF

Last updated: